ARTICLE | Product Development
As U.S. pulls Lilly's monotherapy, Regeneron combo appears most effective against COVID variants
U.S. pulls Lilly’s COVID mAb for lack of potency against variants, but says mAb combos still effective
March 26, 2021 1:16 AM UTC
Resistance of rising SARS-CoV-2 variants to Lilly’s bamlanivimab monotherapy is not necessarily an indicator of what’s to come for other antiviral COVID-19 mAbs.
Eli Lilly and Co. (NYSE:LLY) and the U.S. government stopped distributing the mAb nationwide on Wednesday because of a “sustained increase in SARS-CoV-2 viral variants in the United States that are resistant to bamlanivimab administered alone, and the availability of other authorized monoclonal antibody therapies that are expected to retain activity to these variants.”...